Ignite Creation Date:
2024-05-06 @ 12:06 AM
Last Modification Date:
2024-10-26 @ 10:45 AM
Study NCT ID:
NCT01499160
Status:
TERMINATED
Last Update Posted:
2022-02-11
First Post:
2011-12-14
Brief Title:
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer
Status:
TERMINATED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
low accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
About a third of patients with breast cancer are usually treated by hormone pills called tamoxifen and aromatase inhibitors Aromatase inhibitors are drugs that stop female hormone production Female hormone or estrogen is an important hormone for the growth of breast cancer cells Letrozole is one of the aromatase inhibitors that is approved by the FDA and has been used to treat breast cancer since 1997 However hormone pills usually work for about 6-10 months in most patients Later on breast cancer will start to grow again This condition when hormone pills or endocrine therapy no longer work is called endocrine resistant breast cancer The scientists here at University of Maryland have discovered how these cancer cells can become resistant to hormone pills In our laboratory tests the investigators found that lapatinib and everolimus can reverse this resistance and make letrozole work again However it is not known if the drugs can reverse the resistance in humans
The purpose of this study is to find out whether the combination of letrozole lapatinib and everolimus is effective in women with breast cancer when hormone pills no longer work
Lapatinib is an anti-cancer drug that is already approved by the Food and Drug Administration FDA It is the standard of care for the treatment of a particular type of breast cancer called human epithelial growth factor receptor 2 HER2-positive breast cancer HER2 is a protein involved in the growth of some cancer cells This study will also include patients with HER2-negative breast cancer This means that the cancer cells in these patients do not depend on the HER2 protein The use of lapatinib in these patients is considered experimental
Everolimus is also an anti-cancer drug that is approved by the FDA for kidney cancer Initial studies in mice and later studies in women with breast cancer have shown that everolimus may also slow the growth of breast cancer The use of everolimus is experimental in this study
The purpose of this study is to find out whether the combination of letrozole lapatinib and everolimus is effective in women with breast cancer when hormone pills no longer work
Lapatinib is an anti-cancer drug that is already approved by the Food and Drug Administration FDA It is the standard of care for the treatment of a particular type of breast cancer called human epithelial growth factor receptor 2 HER2-positive breast cancer HER2 is a protein involved in the growth of some cancer cells This study will also include patients with HER2-negative breast cancer This means that the cancer cells in these patients do not depend on the HER2 protein The use of lapatinib in these patients is considered experimental
Everolimus is also an anti-cancer drug that is approved by the FDA for kidney cancer Initial studies in mice and later studies in women with breast cancer have shown that everolimus may also slow the growth of breast cancer The use of everolimus is experimental in this study
Detailed Description:
This is a single-institution clinical trial Patients will be stratified according to the HER2 status
Group 1 HER2-positive in the tumor tissue Group 2 HER2 negative in the tumor tissue
In the first part of the study all of the patients will receive the combination of lapatinib 1500 mgday and letrozole 25 mgday We do not expect any significant toxicity from this combination since the previous study of lapatinib and letrozole showed that this combination is safe with no grade 3-4 toxicities observed Restaging scans CT scan MRI or bone scan will be obtained after every 12 weeks of treatment In those patients who progress from any group everolimus 5 mgday will be added to letrozole and lapatinib will be reduced to 1250 mgday as per the SWOG phase I study of lapatinib and everolimus The outcome of each group will continue to be assessed separately We do not expect to see additional serious toxicity from adding everolimus to the combination of lapatinib and letrozole All of the treatment will be continued until disease progression
Group 1 HER2-positive in the tumor tissue Group 2 HER2 negative in the tumor tissue
In the first part of the study all of the patients will receive the combination of lapatinib 1500 mgday and letrozole 25 mgday We do not expect any significant toxicity from this combination since the previous study of lapatinib and letrozole showed that this combination is safe with no grade 3-4 toxicities observed Restaging scans CT scan MRI or bone scan will be obtained after every 12 weeks of treatment In those patients who progress from any group everolimus 5 mgday will be added to letrozole and lapatinib will be reduced to 1250 mgday as per the SWOG phase I study of lapatinib and everolimus The outcome of each group will continue to be assessed separately We do not expect to see additional serious toxicity from adding everolimus to the combination of lapatinib and letrozole All of the treatment will be continued until disease progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GCC 0901 | OTHER | University of Maryland Greenebaum Cancer Center | None |